Journal article
Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination
Abstract
By conferring systemic protection and durable benefits, cancer immunotherapies are emerging as long-term solutions for cancer treatment. One such approach that is currently undergoing clinical testing is a therapeutic anti-cancer vaccine that uses two different viruses expressing the same tumor antigen to prime and boost anti-tumor immunity. By providing the additional advantage of directly killing cancer cells, oncolytic viruses (OVs) …
Authors
Roy DG; Geoffroy K; Marguerie M; Khan ST; Martin NT; Kmiecik J; Bobbala D; Aitken AS; de Souza CT; Stephenson KB
Journal
Nature Communications, Vol. 12, No. 1,
Publisher
Springer Nature
DOI
10.1038/s41467-021-22929-z
ISSN
2041-1723
Associated Experts
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
Adjuvants, ImmunologicAnimalsAntigens, NeoplasmCancer VaccinesCell Line, TumorClinical Trials, Phase I as TopicClinical Trials, Phase II as TopicDisease Models, AnimalFemaleHumansMiceNeoplasmsOncolytic VirotherapyOncolytic VirusesPoly I-CVaccines, SubunitVaccinia virusVesicular stomatitis Indiana virusXenograft Model Antitumor Assays